Cross-Sector entity
John Kao is most often covered alongside Alignment Healthcare, which appears in 2 of these 2 stories. The 18-day window averages about 0.8 stories each week. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
2 verified stories tracked
Last mentioned: Mar 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
John Kao is most often covered alongside Alignment Healthcare, which appears in 2 of these 2 stories. The 18-day window averages about 0.8 stories each week. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 5 original sources on average. John Kao appears in 2 tracked Cross-Sector stories published from February 25, 2026 through March 14, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering John Kao. Shared-story counts are live from our verified record — not editorial picks.
Insider Selling
President and another insider sell a combined 33,157 shares.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Secondary Offering
Company prices 13.2M shares at $19.46 to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.
